Despite Lacking Profits Arcus Biosciences (NYSE:RCUS) Seems To Be On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Arcus Biosciences(RCUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arcus Biosciences reported that they have over $1 billion of cash on hand, which
Arcus Biosciences Price Target Maintained With a $30.00/Share by Wedbush
Arcus Biosciences Price Target Maintained With a $30.00/Share by Wedbush
Wedbush: The Arcus Biosciences (RCUS.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $30.00.
Wedbush: The Arcus Biosciences (RCUS.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $30.00.
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 87.5% Wedbush → $30 Reiterates Outperform → Outperform 03/25/2024 212.5% Truist Securities → $5
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Beats $(0.98) Estimate, Sales $145.000M Beat $33.862M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.98) by 94.9 percent. This is a 95.41 percent increase over losses of $(1.0
Arcus Biosciences | 10-Q: Quarterly report
Arcus Biosciences 1Q Rev $145M >RCUS
Arcus Biosciences 1Q Rev $145M >RCUS
Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M
04:03 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M
Arcus Biosciences 1Q Loss $4M >RCUS
Arcus Biosciences 1Q Loss $4M >RCUS
Arcus Biosciences 1Q Loss/Shr 5c >RCUS
Arcus Biosciences 1Q Loss/Shr 5c >RCUS
No Data